351 related articles for article (PubMed ID: 35806051)
1. Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives.
Sener U; Ruff MW; Campian JL
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806051
[TBL] [Abstract][Full Text] [Related]
2. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
Wang C; Yu M; Zhang W
Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
[TBL] [Abstract][Full Text] [Related]
3. Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities.
Maccari M; Baek C; Caccese M; Mandruzzato S; Fiorentino A; InternĂ² V; Bosio A; Cerretti G; Padovan M; Idbaih A; Lombardi G
Oncologist; 2024 Apr; 29(4):289-302. PubMed ID: 38048782
[TBL] [Abstract][Full Text] [Related]
4. Emerging therapies for glioblastoma: current state and future directions.
Rong L; Li N; Zhang Z
J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of glioblastoma: Recent advances and future prospects.
Yuan B; Wang G; Tang X; Tong A; Zhou L
Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
[TBL] [Abstract][Full Text] [Related]
6. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies.
Choi BD; Maus MV; June CH; Sampson JH
Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589
[TBL] [Abstract][Full Text] [Related]
8. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
10. Current Immunotherapies for Glioblastoma Multiforme.
Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
Front Immunol; 2020; 11():603911. PubMed ID: 33767690
[TBL] [Abstract][Full Text] [Related]
11. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
12. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
Li Y; Sharma A; Maciaczyk J; Schmidt-Wolf IGH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163235
[TBL] [Abstract][Full Text] [Related]
13. Current State of Immunotherapy for Treatment of Glioblastoma.
McGranahan T; Therkelsen KE; Ahmad S; Nagpal S
Curr Treat Options Oncol; 2019 Feb; 20(3):24. PubMed ID: 30790064
[TBL] [Abstract][Full Text] [Related]
14. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
[No Abstract] [Full Text] [Related]
15. Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma.
Verma A; Rafiq S
Cancer Treat Res; 2022; 183():161-184. PubMed ID: 35551659
[TBL] [Abstract][Full Text] [Related]
16. A review of glioblastoma immunotherapy.
Medikonda R; Dunn G; Rahman M; Fecci P; Lim M
J Neurooncol; 2021 Jan; 151(1):41-53. PubMed ID: 32253714
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
18. The Role of Checkpoint Inhibitors in Glioblastoma.
Desai K; Hubben A; Ahluwalia M
Target Oncol; 2019 Aug; 14(4):375-394. PubMed ID: 31290002
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological targeting of the tumor-immune symbiosis in glioblastoma.
Pang L; Khan F; Dunterman M; Chen P
Trends Pharmacol Sci; 2022 Aug; 43(8):686-700. PubMed ID: 35534356
[TBL] [Abstract][Full Text] [Related]
20. Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.
Ren PP; Li M; Li TF; Han SY
Curr Pharm Des; 2017; 23(14):2113-2116. PubMed ID: 28302023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]